Showing results (101-110 of 114) with videos related to
Sort By:
Pageof 12
Breast Cancer Research and Treatment|February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.Journal for Immunotherapy of Cancer|December 1, 2019
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, et al.Cancer Prevention Research (Philadelphia, Pa.)|September 3, 2011
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozoleTatiana M Prowell, Amanda L Blackford, Celia Byrne, et al.Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.Cancer Research Communications|March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid TumorsMark Yarchoan, John D Powderly, Bruno R Bastos, et al.Journal for Immunotherapy of Cancer|September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.Journal of Translational Medicine|June 7, 2022
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, et al.Nature Communications|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.Journal for Immunotherapy of Cancer|October 20, 2019
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumorsLi Zhu, Jessica L Narloch, Sayali Onkar, et al.Breast Cancer Research and Treatment|November 15, 2011
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancerMichaela J Higgins, Tatiana M Prowell, Amanda L Blackford, et al.Pageof 12